Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Diabetes Centre, Tameside Hospital NHS Foundation Trust and University of Manchester, Manchester, UK.
Diabet Med. 2019 Sep;36(9):1133-1140. doi: 10.1111/dme.13985. Epub 2019 Jun 13.
To assess the impact of autologous cell therapy on critical limb ischaemia in people with diabetes and diabetic kidney disease.
A total of 59 people with diabetes (type 1 or type 2) and critical limb ischaemia, persisting after standard revascularization, were treated with cell therapy in our foot clinic over 7 years; this group comprised 17 people with and 42 without severe diabetic kidney disease. The control group had the same inclusion criteria, but was treated conservatively and comprised 21 people with and 23 without severe diabetic kidney disease. Severe diabetic kidney disease was defined as chronic kidney disease stages 4-5 (GFR <30 ml/min/1.73 m²). Death and amputation-free survival were assessed during the 18-month follow-up; changes in transcutaneous oxygen pressure were evaluated at 6 and 12 months after cell therapy.
Transcutaneous oxygen pressure increased significantly in both groups receiving cell therapy compared to baseline (both P<0.01); no significant change in either of the control groups was observed. The cell therapy severe diabetic kidney disease group had a significantly longer amputation-free survival time compared to the severe diabetic kidney disease control group (hazard ratio 0.36, 95% CI 0.14-0.91; P=0.042); there was no difference in the non-severe diabetic kidney disease groups. The severe diabetic kidney disease control group had a tendency to have higher mortality (hazard ratio 2.82, 95% CI 0.81-9.80; P=0.062) than the non-severe diabetic kidney disease control group, but there was no difference between the severe diabetic kidney disease and non-severe diabetic kidney disease cell therapy groups.
The present study shows that autologous cell therapy in people with severe diabetic kidney disease significantly improved critical limb ischaemia and lengthened amputation-free survival in comparison with conservative treatment; however, the treatment did not influence overall survival.
评估自体细胞疗法对合并糖尿病和糖尿病肾病的肢体严重缺血患者的影响。
在我们的足部诊所,7 年内对 59 名合并糖尿病(1 型或 2 型)且严重肢体缺血的患者进行了细胞治疗,这些患者在标准血运重建后仍存在肢体严重缺血;其中 17 名患者合并严重糖尿病肾病,42 名患者无严重糖尿病肾病。对照组也符合相同的纳入标准,但采用保守治疗,包括 21 名合并严重糖尿病肾病的患者和 23 名无严重糖尿病肾病的患者。严重糖尿病肾病定义为慢性肾脏病 4-5 期(肾小球滤过率<30 ml/min/1.73 m²)。在 18 个月的随访期间评估死亡率和免于截肢的生存率;在细胞治疗后 6 个月和 12 个月评估经皮氧分压的变化。
与基线相比,接受细胞治疗的两组患者的经皮氧分压均显著升高(均 P<0.01);而对照组的两组患者均未观察到明显变化。与严重糖尿病肾病对照组相比,严重糖尿病肾病细胞治疗组的免于截肢生存率显著延长(风险比 0.36,95%可信区间 0.14-0.91;P=0.042);在非严重糖尿病肾病组之间没有差异。严重糖尿病肾病对照组的死亡率有升高趋势(风险比 2.82,95%可信区间 0.81-9.80;P=0.062),高于非严重糖尿病肾病对照组,但严重糖尿病肾病和非严重糖尿病肾病细胞治疗组之间没有差异。
本研究表明,与保守治疗相比,自体细胞疗法可显著改善合并严重糖尿病肾病的患者的肢体严重缺血,并延长免于截肢的生存率;然而,该治疗方法并未影响总体生存率。